Walgreens' Houston distribution center at 1805 Greens Road went dark on Monday, June 1, taking 159 warehouse and logistics positions with it. The closure is the supply-chain piece of a broader 628-job restructuring that Walgreens disclosed in WARN filings this winter — 469 corporate roles at the Deerfield, Illinois headquarters, plus the Houston DC — and the first major Sycamore Partners-era cut to actually hit a fulfillment node rather than the C-suite.
The timing is the story. Sycamore closed on its $10 billion take-private of Walgreens Boots Alliance in February. The Texas Workforce Commission WARN notice landed on February 18, three weeks after the deal closed. The 14-week countdown to June 1 is, by private-equity standards, an unusually fast trigger on a physical asset — and a signal that Sycamore's playbook is running ahead of the schedule that Walgreens telegraphed during the sale process. A Walgreens spokesperson told Retail Dive that the company is "simplifying its organization to speed up decision-making" — the standard PE-era euphemism for cost extraction.
For retail and supply-chain operators reading the tea leaves, three things matter here. First, the Houston DC was a regional fulfillment node serving the Texas Gulf Coast — meaning replenishment to roughly 1,000 surrounding Walgreens stores now has to be re-routed through other Sycamore-rationalized DCs. That kind of network re-stitching usually surfaces as out-of-stocks at the shelf two to three quarters out, not immediately. Second, the dual hit of corporate and logistics roles in a single restructuring wave suggests Sycamore is compressing the timeline that prior management telegraphed as a multi-year wind-down. And third, the broader Walgreens store-closure schedule — which Coresight tracking has Walgreens leading among 2026 closures — now has a logistics-capacity rationale behind it, not just a "we lost money on these stores" rationale.
This puts Walgreens in distinct company. Sycamore's last big retail bet — Staples — followed a similar choreography: take-private, fast cost-out, network rationalization, then either an IPO exit or a strategic sale. The challenge with Walgreens is scale: there are roughly 8,000 U.S. stores in the network, the prescription side is essentially a regulated utility, and CVS and Amazon Pharmacy are both pricing prescription fulfillment as a loss-leader to acquire health-system relationships. A Sycamore-style rip-and-replace works when the asset is a commodity. Walgreens, awkwardly, sits halfway between commodity (front-of-store) and franchise (pharmacy), and the cost extraction that's easy on the corporate side gets harder once you start pulling capacity out of the supply chain.
The pharmacy industry has been telling itself a "consolidation creates strength" story since at least 2019. Sycamore's job is to test that thesis. The Houston DC was a small piece of that test. The bigger pieces — the rumored sale of the Boots UK business, the previously reported Pakistan-based BPO build-out, and the next wave of U.S. store closures — will arrive over the back half of 2026. For workers in Houston, the academic debate is over. For everyone else in the pharmacy aisle, this is the year the experiment runs in public.
Severance and outplacement support are being offered to affected employees, per company statements, though specific terms have not been disclosed.